An Evidence-based Approach to the Diagnosis and Treatment of COPD: Improving Patient Care
| Title: | An Evidence-based Approach to the Diagnosis and Treatment of COPD: Improving Patient Care |
| Topic: | Pulmonary Disease |
| Relevant Terms: | Bronchodilators, COPD, Respiratory, Spirometry |
| Primary Audience: | Family and General Practice Physicians, Internal Medicine Physicians, Primary Care Physicians |
| Launch Date: | 30-Dec-11 |
| Credits: | 0.75 AMA PRA Category 1 Credit™ |
| Expiration Date: | The accreditation for this activity has expired. |
Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Implement evidence-based recommendations for the accurate diagnosis and appropriate treatment of patients with chronic obstructive pulmonary disease (COPD)
- Recognize when long-acting therapy is appropriate for patients with frequent COPD symptoms or exacerbations
- Develop treatment plans that incorporate patients' needs, preferences, and lifestyle to optimize adherence to treatment
Faculty
Estimated Time to Complete Activity: 0.75 hours
Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Integrity Continuing Education designates this Internet activity for 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Integrity Continuing Education designates this Internet activity for 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Amir Sharafkhaneh, MD, PhD
Consultant: Dey Pharma, GlaxoSmithKline
Research/Grants: GlaxoSmithKline
Speakers' Bureau: Boehringer Ingelheim, Dey Pharma, GlaxoSmithKline, Pfizer
Sean M. Gregory, PhD, hereby states that he or his spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Media
Internet
Media
Internet
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. During the period of December 30, 2011 through December 30, 2012, participants must:
Hardware/Software Requirements
Windows: Internet Explorer 6, Internet Explorer 7, Firefox 1.x and later, Safari 3, Google Chrome, Opera 9.5
Macintosh: Firefox 1.x and later, Safari 3
Linux: Firefox 1.x
Disclosure of Unlabeled Use
There are no fees for participating and receiving CME credit for this enduring activity. During the period of December 30, 2011 through December 30, 2012, participants must:
- Read the learning objectives and faculty disclosure
- Study the educational activity
- Complete the posttest and evaluation form following the activity
Hardware/Software Requirements
Windows: Internet Explorer 6, Internet Explorer 7, Firefox 1.x and later, Safari 3, Google Chrome, Opera 9.5
Macintosh: Firefox 1.x and later, Safari 3
Linux: Firefox 1.x
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Inc., and Dey Pharma, L.P., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Dey Pharma, L.P. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Commercial Support
This educational activity is supported by an educational grant from Dey Pharma, L.P.
Integrity Continuing Education
For questions about the accreditation of this activity, please contact Integrity Continuing Education at 888-255-1009 or info@integrityce.com.
Commercial Support
This educational activity is supported by an educational grant from Dey Pharma, L.P.
Integrity Continuing Education
For questions about the accreditation of this activity, please contact Integrity Continuing Education at 888-255-1009 or info@integrityce.com.



